Tonix’s depression fail; Lilly exercises option in Sitryx deal; Milner stops fight against Abcam acquisition

Tonix drops de­pres­sion drug af­ter PhII fail­ure: Tonix Phar­ma­ceu­ti­cals is dis­con­tin­u­ing its ma­jor de­pres­sive dis­or­der pro­gram, TNX-601 ER, af­ter a mid-stage dis­ap­point­ment. The oral for­mu­la­tion of tianep­tine missed sta­tis­ti­cal sig­nif­i­cance for the pri­ma­ry end­point of change from base­line in de­pres­sion sever­i­ty, which is mea­sured us­ing the Mont­gomery-Ås­berg De­pres­sion Rat­ing Scale. The com­pa­ny’s share price $TNXP plum­met­ed about 17% to $0.48 on Wednes­day af­ter the news was an­nounced. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.